Kemnay Advisory Services’s Veracyte VCYT Stock Holding History

Kemnay Advisory Services’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.8K	Buy	711 +63	+10%	+$2.64K	0.01%	354
2026 Q1	$20.9K	Buy	648 +511	+373%	+$18.9K	﹤0.01%	660
2025 Q4	$5.77K	Buy	+137	New	+$5.52K	﹤0.01%	832

Other funds holding VCYT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Kemnay Advisory Services's VCYT Position: Q2 2026 in Review

Kemnay Advisory Services increased its Veracyte (VCYT) stake by 9.7% in Q2 2026, buying an estimated $2.64K and bringing the position to 711 shares worth $41.8K. The position accounts for 0.01% of the portfolio, ranked #354.

Kemnay Advisory Services first reported a position in VCYT in Q4 2025 and has held it in 3 quarters since. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

Kemnay Advisory Services held 711 shares of Veracyte worth $41.8K as of Q2 2026.
Kemnay Advisory Services bought 63 Veracyte shares in Q2 2026, an estimated $2.64K.
Veracyte made up 0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #354 holding.
Kemnay Advisory Services first reported a position in Veracyte in Q4 2025 and has held it in 3 quarters since.
370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.